MedGene Therapeutics develops advanced T cell therapies using its PBL-T platform, which selects highly tumor-reactive circulating tumor-infiltrating lymphocytes (TIL) from a patient's peripheral blood, and the RIV-8 technology, which prevents T cell exhaustion through genetic reprogramming. The company targets solid tumors with high unmet medical needs, offering a less invasive method for TIL collection and improved T cell quality compared to conventional approaches.
Funding
Funding not disclosed
Founders
Product
Problem
Current T cell therapies for solid tumors face challenges in obtaining sufficient numbers of tumor-reactive T cells, often requiring invasive procedures. Additionally, T cell exhaustion can limit the effectiveness and durability of these therapies.
Solution
MedGene Therapeutics is developing cell therapies for solid tumors using two core technologies: PBL-T and RIV-8. The PBL-T platform selects highly tumor-reactive, circulating tumor-infiltrating lymphocytes (TIL) directly from a patient's peripheral blood, offering a less invasive method of T cell collection. The RIV-8 technology employs genetic reprogramming to prevent T cell exhaustion, potentially enhancing the persistence and efficacy of the therapeutic T cells. By combining these technologies, MedGene aims to create more effective and accessible T cell therapies for solid tumors.
Target Audience
The primary target audience includes patients with solid tumors who have unmet medical needs, as well as clinicians and researchers seeking more effective and less invasive T cell therapy options.
Features
- PBL-T platform: Selects neoantigen-specific CD8+ T cells from peripheral blood.
- Less invasive sample collection compared to traditional TIL therapies.
- Enhanced T cell quality with a less exhausted and more stem-like phenotype.
- RIV-8 technology: Genetic reprogramming to prevent T cell exhaustion.
- RIV-8 can reinvigorate even terminally exhausted T cells.
- RIV-8 is applicable to various adoptive cell therapies (CAR-T, TCR-T, TIL) and checkpoint inhibitors (CPI).
- Multiple delivery options for RIV-8, including AAV, mRNA, and nanoparticles.